Trial · NCT04322890
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
NCT04322890, Phase 2, Recruiting, Hunan Province Tumor Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation. Trials, record NCT04322890. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04322890
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
- NCT number
- NCT04322890
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 6,000 participants, estimated
- Lead sponsor
- Hunan Province Tumor Hospital
- Conditions
- Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation
- Interventions
- Osimertinib, Alectinib 150 MG, Crizotinib 250 MG, Savolitinib, Crizotinib., Chemotherapy
- First posted
- 2020-03-26
- Last updated
- 2024-10-22
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | Time from first subject dose to study completion, or up to 36 month | To assess progression-free survival of patients treated with target treatment according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator, define as first dose to first documented disease progression assessed by investigator or death due to any cause. |
| Secondary | Overall survival (OS) | To assess overall survival, define as first dose to the death of the subject due to any cause up to 5 years | To assess overall survival, define as first dose to the death of the subject due to any cause |
| Secondary | Objective Response Rate (ORR) | Time from first subject dose to study completion, or up to 36 month | To assess progression-free survival of patients treated with target treatment according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by investigator, define as first dose to first documented disease progression assessed by investigator or death due to any cause. |
| Secondary | Adverse events (AEs) according to CTCAE 5.0 | From first dose until 28 days after the last dose, up to 24 month | Number of participants with adverse events (AEs) according to CTCAE 5.0 |
| Secondary | Patient reported outcome (PRO) | To assess overall survival, define as first dose to the death of the subject due to any cause up to 5 years | Patient reported outcome defined as the quality of life during the whole process treatment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04322890
GET https://conductscience.org/api/trials/v1/NCT04322890/registered